HIV

The 25th International AIDS Conference took place July 22-26 in Munich, Germany, and one of the sessions delved into the potential impact of civil society laws on the 95-95-95 targets as laid out in the UNAIDS Global AIDS Strategy for 2021 to 2026.

Systemic racism, including the practice of redlining, has had an enduring effect on health outcomes in people living with HIV, including time to viral suppression.

Follow-up in men living with HIV who have sex with men should be performed to assess quality of life due to sexual function.

In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why stigma and shame continue to attach themselves to an HIV diagnosis and why policy efforts to overcome both must persist.

Goals including addressing all of hunger and food insecurity, unmet needs for mental health services, and unstable housing or homelessness in people living with HIV are unlikely to meet their 2025 thresholds.

Drug use, participation in exchange sex, and depressive symptoms were all found to be associated with bacterial sexually transmitted infections (STIs) in sexual minority men living with HIV.

There were no significant differences found between people with and without HIV when it came to their periodontal profile.

At the 25th International AIDS Conference, Emmanuel Nazaire Essam, MD, MPH, presented the analysis, "Medicaid Insurance Expansion and Its Association With HIV Outcomes in Nebraska, USA: An Observational Prospective Cohort Study."

A federal judge determined that all people being actively treated for HIV can enlist in the military.

At AIDS 2024 in July, Kelly Dyer, MD, Perelman School of Medicine, presented research findings from an investigation at the intersection of health equity, substance use detox, infectious disease screening, and patient harm reduction.

Jennifer Cocohoba, PharmD, MAS, AAHIVP, University of California, San Francisco, School of Pharmacy, discusses the benefits of pharmacy-administered long-acting injectable antiretroviral therapy for HIV and patient attitudes toward pharmacy-administered treatment.

A trio of posters presented at AIDS 2024, the 25th International AIDS Conference, explored widespread disparities in access to pre-exposure prophylaxis (PrEP) and how to make access more equitable, both globally and locally.

For the recent AIDS 2024 conference, we spoke with Nishita Dsouza, PhD, MPH, Columbia University School of Social Work Social Intervention Group, who presented research on HIV and sexually transmitted infection prevention among Black women with criminal legal system involvement.

In part 1 of this interview, Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), explained the research she presented at the 25th International AIDS Conference and the disparities migrant workers continue to encounter in HIV care.

We spoke with Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), who advocates at regional and global levels for policy reform of discriminatory practices that put migrant workers at risk of HIV and AIDS.

This research presented at AIDS 2024 shows that cognitive behavioral therapy (CBT) groups help to fill an unmet need among older persons living with HIV: to overcome the age-related health disparities this group experiences from being in long-term care and improve their health outcomes.

Patricia Cioe, PhD, presented data at AIDS 2024 from a study that investigated the impact of peer support on people living with HIV who smoke, a group for whom there are higher rates of cardiac events and cancer.

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

A federal appeals court ruled yesterday that a group of Republican-led states do not have legal standing to impose restrictions on the abortion pill mifepristone; the US infant mortality rate increased by 3% in 2022; a twice-yearly injection could prevent 100% of HIV infections.

A late-breaking abstract focused on a head-to-head comparison between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) in the treatment of HIV.

The combination of a high proportion of new diagnoses of HIV with the high prevalence of HIV indicate that an epidemic of HIV could be growing.

Interventions for female sex workers in Tanzania could help in reducing the incidence of HIV in this population.

Men who have sex with men who are living with HIV were found to have a significant burden of both hepatitis B and C infections.

Jared Baeten, MD, PhD, discusses when lenacapavir could be available for the prevention of HIV, as well as other trials in the PURPOSE program.

Jared Baeten, MD, PhD, discusses the significance of the PURPOSE 1 trial results, which found that lenacapavir for pre-exposure prophylaxis resulted in no new infections of HIV.